1887

Abstract

Pneumococcal conjugate vaccine to seven capsular types has been highly effective in the US since its introduction in 2000. The same vaccine was adopted by the UK in 2006. Ongoing surveillance since 1995 of invasive pneumococcal disease (IPD) in Oxfordshire, UK, allowed assessment of the impact of vaccine intervention. The vaccine significantly reduced IPD among the target group, children under 2 years of age; incidence rate ratio (IRR)=0.62 (95 % CI 0.43–0.90) (=0.008) comparing the 3 years pre- and post-implementation with a residual incidence of 22.4/100 000 children. The reduction was even greater when comparing 11 years pre- with the 3 years post-implementation of vaccine; IRR=0.53 (0.39–0.70) (<0.0001). There was a marked direct effect of the vaccine evidenced by substantial reductions in the seven serotypes contained in the vaccine. There was also a clear reduction in IPD for those serotypes contained in the vaccine among those older than 2 years when comparing both the 3 and 11 year pre-PCV7 time periods, with IRR=0.57 (0.47–0.69) (<0.0001) and IRR=0.50 (0.43–0.58) (<0.0001), respectively, indicating a strong herd effect. There was a significant, though moderate, rise in the serotypes not contained in the vaccine, with clear evidence for replacement in some serotypes.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.023135-0
2011-01-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/1/91.html?itemId=/content/journal/jmm/10.1099/jmm.0.023135-0&mimeType=html&fmt=ahah

References

  1. Beekmann, S. E., Heilmann, K. P., Richter, S. S., García-de-Lomas, J. & Doern, G. V., GRASP Study Group ( 2005; ). Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 25, 148–156.[CrossRef]
    [Google Scholar]
  2. CDC ( 2005; ). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54, 893–897.
    [Google Scholar]
  3. CDC ( 2008; ). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction – eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 57, 144–148.
    [Google Scholar]
  4. Foster, D., Knox, K., Walker, A. S., Griffiths, D. T., Moore, H., Haworth, E., Peto, T., Brueggemann, A. B. & Crook, D. W. on behalf of the Oxford Invasive Pneumococcal Surveillance Group ( 2008; ). Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol 57, 480–487.[CrossRef]
    [Google Scholar]
  5. Hausdorff, W. P., Bryant, J., Paradiso, P. R. & Siber, G. R. ( 2000a; ). Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part 1. Clin Infect Dis 30, 100–121.[CrossRef]
    [Google Scholar]
  6. Lexau, C. A., Lynfield, R., Danila, R., Pilishvili, T., Facklam, R., Farley, M. M., Harrison, L. H., Schaffner, W., Reingold, A. & other authors ( 2005; ). Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294, 2043–2051.[CrossRef]
    [Google Scholar]
  7. Pilishvili, T., Lexau, C., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Reingold, A., Thomas, A., Schaffner, W. & other authors ( 2010; ). Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201, 32–41.[CrossRef]
    [Google Scholar]
  8. Robinson, K. A., Baughman, W., Rothrock, G., Barrett, N. L., Pass, M., Lexau, C., Damaske, B., Stefonek, K., Barnes, B. & other authors ( 2001; ). Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998. Opportunities for prevention in the conjugate vaccine era. JAMA 285, 1729–1735.[CrossRef]
    [Google Scholar]
  9. Rodenburg, G. D., de Greeff, S. C., Jansen, A. G., de Melker, H. E., Schouls, L. M., Hak, E., Spanjaard, L., Sanders, E. A. & van der Ende, A. ( 2010; ). Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 16, 816–823.[CrossRef]
    [Google Scholar]
  10. Scott, D. A., Komjathy, S. F., Hu, B. T., Baker, S., Supan, L. A., Monahan, C. A., Gruber, W., Siber, G. R. & Lockhart, S. P. ( 2007; ). Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 25, 6164–6166.[CrossRef]
    [Google Scholar]
  11. Sleeman, K., Knox, K., George, R., Miller, E., Waight, P., Griffiths, D., Efstratiou, A., Broughton, K., Mayon-White, R. T. & other authors ( 2001; ). Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 183, 239–246.[CrossRef]
    [Google Scholar]
  12. van Gils, E. J., Veenhoven, R. H., Hak, E., Rodenburg, G. D., Bogaert, D., Ijzerman, E. P., Bruin, J. P., van Alphen, L. & Sanders, E. A. ( 2009; ). Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302, 159–167.[CrossRef]
    [Google Scholar]
  13. Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., Reingold, A., Cieslak, P. R., Pilishvili, T. & other authors ( 2003; ). Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348, 1737–1746.[CrossRef]
    [Google Scholar]
  14. WHO ( 2007; ). Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol Rec 82, 93–104.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.023135-0
Loading
/content/journal/jmm/10.1099/jmm.0.023135-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error